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ABSTRACT
CINDY L. BRISTOW.

Role of Serum Amyloid P Component in Immune
Clearance.
(Under the direction of Dr. Robert J. Boackle.)

In order to clarify the mechanism of interaction of serum amyloid P
component (SAP) with complement, the interaction of SAP with Clq was

4B in the presence of

studied.

It is known that SAP binds Sepharose

calcium.

1 2 5I-Clq was retained on the Sepharose when purified 1 2 5I-Clq

was incubated with SAP prior to affinity chromatography on Sepharose.

In the absence of SAP, the 125I-Clq was not retained. To further examine
the interaction of SAP with Clq, SAP was incubated at
with Clq.

va~ing

ratios

These mixtures were examined via crossed immunoelectro-

immunoelectrophoresis against goat anti-SAP.

A change in the

electrophoretic behavior of SAP was observed in the presence of Clq.
was found that SAP interacted with the collagen-like stem of Clq.

It

In

these studies, 1 2 5r-SAP was incubated with pepsin digests of Clq in a

microtitre solid-phase binding assay.

In addition, a microtltre

solid-phase binding assay was utilized in order to investigate the
possible binding of SAP with IgG.

Interestingly, human IgG and Fabr

but not Fc~, were found to bind 125I_SAP~

Furthermore, 125I-SAP-IgG

complexes bound to immobilized Clq, whereas 125I-SAP-Clq complexes
,demonstrated significantly less binding to IgG.

,

iii
The ability of SAP to activate complement as detected by C3
conversion was studied.

It was found that SAP activated complement to a

limited extent in normal human serum but caused extensive C3 conversion
when serum from an individual with decreased levels of Cl inhibitor was
used.

Furthermore, the activation of the complement pathway by SAP in

the latter serum was reversed by the addition of exogenous Cl inhibitor,
indicating that SAP has the ability to playa role in the regulation of
complement via the classical pathway.
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CHAPTER 1

BIOCHEMICAL AND BIOLOGICAL CHARACTERISTICS OF
HUMAN SERUM AMYLOID P COMPONENT AND Clq

2

I.

Biochemical and biological characteristics of human SAP

A.

Biochemical characteristics of SAP.

1.

Amyloid P component in amyloid deposits.

Amyloidosis is an epiphenomenon which occurs as a result of
prolonged acute phase responses in cases of chronic inflammation and
prolonged stimulation of the reticuloendothelial system.

Character--.

istic of this enigmatic disease is the deposition of proteinacious
fibrils at various organ sites depending on the nature of the primary
disease.

The etiology of amyloidosis is not known, but the composition

of amyloid deposits has been established.

The disease has been

classified as "primary" when the amyloid fibrils are composed of light
chains of immunoglobulin (1) and "secondary" when the fibrils are
composed of amyloid A protein (2), an acute phase reactant of unknown
function.

Other forms of amyloidosis have been reported where the

fibrillar component is neither amyloid A component nor immunoglobulin
light chain.

For example, pre-albumin (3) and{32microglobulin (4) have

been identified to be the fibrillar component in isolated cases.

In

cases of amyloidosis; regardless of the nature of the fibril component,
there is another associated protein, amyloid P component (AP) which

does not form fibrils, but is found bound to the fibrils in amyloid
deposits (2).

3
2.

Localization of amyloid P component in tissue.

Amyloid P was first detected in amyloid deposits.

Later it was

demonstrated to be a normal plasma constituent of every vertebrate
species studied (5).

In 1978, SAP was discovered in basement membrane

and was mistakenly thought to be a form of type IV collagen (6).

As

was later discovered, this mis-named, mis-identified, and poorly
understood glycoprotein is a normal matrix constituent in glomerular
basement membrane (7).

Amyloid P has been reported to be covalently

associated with collagen and/or other matrix proteins in basement
membrane (8).

Furthermore, by direct immunofluorescent staining of

normal human tissues with anti-SAP, it was demonstrated that SAP is -associated with elastic fibers in the connective tissue of kidney,
skin, lung, gut, heart, and blood vessels (8).

There is close

morphological association in vivo between amyloid fibrils and
microfibrils of elastic fibers.

Because most amyloid deposits and

inflammatory responses involve basement membranes, the importance of
the localization of SAP in basement membrane is obvious.

3.

Amyloid P component in serum.

Serum amyloid P component (SAP) is a 9.5

S~1-g1ycoprotein

found in plasma as well as in basement membrane (7,8).

(5)

This 250,000

molecular weight glycoprotein has been shown to be antigenically
identical to the amyloid P component found in amyloid deposits (9).
SAP is

made up of 10 identical 23,500 molecular weight subunits

noo-covalently linked to form two face-to-face pentagonal structures
(10).

The similarity in structure and amino acid sequence between

4
SAP, C-reactive protein (CRP) , and hamster female protein (HFP) has led

to the classification of these pentameric proteins as pentraxins

(10,11).
(12).

In humans, SAP, unlike CRP, is not an acute phase reactant

In contrast, CRP is not an acute phase reactant in mouse whereas

SAP is an acute phase reactant (13).

B.y some unnatural twist of fate,

HFP, the hamster counterpart of human SAP and CRP,is an acute phase
reactant in the male but a normal plasma constituent is the female

(13).

This is an interesting characteristic of HFP because it

indicates that the activities of SAP and CRP may be hormonally

controlled in human as well.
SAP has been found in all vertebrate species studied and has never

been found to be deficient in any individual (13).

Furthermore, the

N-terminal amino acid sequence of SAP in plaice, a teleost fish, has

50% homology with human SAP (13).

When the amino acid sequences of

human SAP and CRP are compared, they are almost 70% homologous (14).

Very recently the gene coding for SAP has been localized to chromosome
1 indicating that the SAP gene is probably linked to the gene for CRP

(15).

The evolutionary conservation of SAP indicates it mediates an

important function.

In man, SAP has been found to be present in

concentrations of 10-100 ug/ml with an average of 40 ug/ml (13).

This

level is consistent throughout life and is found to increase only

slightly in chronic inflammatory disease.

The carbohydrate composition of SAP is 11.2% consisting of 5.6%
neutral sugars, 3.0% glucosamine, and 2.6% sialic acid (16).

The

presence of microheterogeneity in SAP has been attributed to amino acid

5
residues as opposed to differences in glycosylation (14), although the

genetic basis for this microheterogeneity has yet to be established.
B.

The biological function of SAP.
1.

The interaction of SAP with the complement system.

a.

The interaction of SAP with the first component of complement.

Although SAP has been extensively characterized biochemically,
little information is available to elucidate its biological function.

Assimeh and painter (16) reported they had identified a fourth
subcomponent of the first component of complement, which they
designated CIt.

The Clt molecule was shown to co-purify with Cl when

serum vas passed through a column containing IgG coupled to Sepharose

(16).

Later, the Clt molecule was found to actually be SAP (17).

It

was shown that SAP had affinity for Sepharose itself, and therefore,
it was suspected that SAP was not actually a subcomponent of Cl (18).
Subsequently, Cooper and Ziccardi (19) showed in a variety of assays
that SAP neither functionally nor physically interacted with C1.
b.

The interaction of SAP with fixed complement.

Although the hypothesis that SAP could interact with the Cl
molecule had been disproved, evidence indicated that SAP might, in
fact, interact with the complement system.

It was shown in 1980 that

SAP could agglutinate complement-coated, antibody-sensitized sheep
erythrocytes in a calcium dependent manner (20).

By

using sera

':defieient for various complement componel!:tJ'r£ ff?u.n' tI:ma.mcrg. tlie.: antii,1)odtvsensitized erythrocytes, it was concluded. i:U:m.tii.

. on the complement-coated erythrocytes witb.,
irreversibly with C3b't it was shown that

agglutinated by SAP (21).
with C3bi.

~tt-·!r.j1':D1fl)ill

~'t1fu

iJniienar.rtJ.ilng(

:iJntiera~tla~

,mdit!it

1i&''eS~ ~]$J wel1e: !,!Q'i ]Wlg~!r~

It -was suggesit~d.1 itftertt. ~) mllig;li1J inrn.e~a1'l1t
t~~l 'Wl!l$ ;:nm;- ~3~ <0.11'

Later these authors showed

interacting with c4 on these
c.

~) ~

erythrocytes~

The interaction of SAP with

C4-b~~~ ~~~~~ ~;

fibronectin.

fibronect in were removed from serum wh6Jn

eluted with EDTA from the

~. W1A.1$

JPla..aadl

iift~u~~.

SAP-Sepharos~ i"Will11mt[: atni~ ~r.~~ anaiLy,z~dJ

the majority of the protein eluted in

(1;

by;'

llidis.~ wal}f.,'

gradient PAGE gel showed a deep-stainilt~~ 1:lmrnll at-n~ a!Y:l.nQlIt:i:ma;tEf11J~ "YlJtette'

Clq would have migrated, although this p€rillntl was:',

nero

Jtt;sc.u.BJ~dt.

Trace proteins in the eluate identifiet ilrnnnmarattemnJ'cai)Jj}..c
IgG, IgA, C3, Clq, CIs, and SAP itself.,

of proteins were also recovered in the

ry]lnc at.g:t&v::al:ant.

Yfff!J&'
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Although the non-SAP bearing Sepharose c1llillu.mn3

w;a;s~;

mft.anit 'tio.;

bff~

a·:.
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adhered to the Sepharose beads at the physiologic concentration of
calcium available thereby setting up a calcium-mediated, SAP-coupled

Sepharose column.

Were SAP to interact with complement directly or

indirectly, it might have caused deposition of native or activated
fragments of complement.

In this case, some complement components

would have become bound to the SAP complexes indirectly, thus leading

to mistaken identification of ligands for the SAP molecule.

Although

purified fibronectin was shown to adhere to the SAP-Sepharose column,
purified C4bp was not similarly tested.

Therefore, it is still

unclear whether C4bp directly interacts with SAP.

The fact that

purified fibronectin interacts with SAP is interesting because these
two proteins are the only normal plasma constituents also found in
'connective tissue.
d.

The activation of C3b receptors on macrophage membranes by

SAP.
Both fibronectin and SAP have been shown to stimulate macrophage
uptake of sheep erythrocytes coated with C3b or C3bi (24) Although
monocytes were unable to become activated to phagocytize C3b- or C3bi-

coated sheep erythrocytes alone, the presence of SAP or fibronectin
promoted phagocytosis through activation of the C3 receptors of the
macrophage (25).

These authors suggested that SAP and fibronectin may

also potentiate phagocytosis of C3-coated pathogens in vivo.
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2.

The interaction of SAP with the coagulation system.

a.

Inhibition of fibrin polymerization by SAP.

As early as

1977

there was a report that amyloid P component

interacted with heparin

(25).

In this abstract, it was reported that

SAP inhibited the ability of heparin to block clot formation.

In 1980,

however, another group claimed that SAP potentiated heparin's
anti-coagulant activity (26).

In 1983, it was shown that SAP and

heparin were both required and synergistic in preventing polymerization
of the fibrin monomer by inhibition of fibrinopeptide A (FPA) release

(27).

It was further shown that SAP and heparin were synergistic in a

system of purified components containing fibrinogen, thrombin,
antithrombin III, SAP, and heparin, and that SAP became incorporated
into the forming fibrin clot.
The interaction of SAP and heparin is very interesting considering

the fact that heparin potentiates several serine protease inhibitors

such as C1 inhibitor (28), Factor H (29), and antithrombin III (30)
which are involved in the regulation of both the coagulation and
complement cascades.

For this and other reasons, it has been suggested

that SAP may be a regulatory protein in the coagulation and complement

systems.
b.

The interaction of SAP with platelets.

It has been demonstrated that heat-aggregated CRP activates
platelets

(31).

Activation was measured as aggregation, secretion, and

generation of thromboxane by platelets.

In subsequent work, it was

shown that SAP had the ability to inhibit platelet activation mediated

9
by heat-aggregated CRP, but not activation mediated by heat-aggregated
IgG, acid-soluble collagen, DNA, ADP, or thrombin (32).

However, since

there is no in vivo counterpart of heat-aggregated CRP, these results

are difficult to interpret.

3.

Effects of SAP on human lymphocytes.

It has recently been reported that SAP has an inhibitory effect on

T cell function as measured

by lymphocyte proliferation induced by

CoDA, PHA, and soluble protein A (33).
enhanced the ability

o~

In addition, SAP minimally

T cells to form E-rosettes.

The significance

of the interaction of SAP with T cells in vivo is unknown.

4. The lectin-like qualities of SAP.
The interaction of SAP with several galactose-specific lectins
including asialo-ceruloplasmin, bovine pneuma galactan, and several
snail galactans has been reported (34).

Interestingly, CRP and Clq

also were shown to form precipitates in agarose when exposed to certain
of these galactans.
It has been demonstrated that SAP bound a non-T, non-B, acute

lymphocytic leukemic (ALL) cell line as well as unseparated PBMe.

Such

binding of SAP was reduced in the presence of a snail galactan polymer

(35).

In these studies, it was shown that SAP suppressed the

proliferation of PBMC and the non-T, non-B, ALL cell line in response
to PPD and PHA.

Similarly, the antibody 'production of PBMC after

stimUlation with PWM was reduced in the presence of SAP.

This

suppression could only be observed when SAP was added within 24 hours
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of initiation of culture.

It was suggested that SAP may serve as an

,endogenous lectin interacting with glycoproteins displaying exposed
;'

galactose residues either in plasma or on cell membranes.
Investigation of the binding specificity of SAP for agarose, a

linear galactan, was recently examined.

It was demonstrated using an

SAP-coupled Sepharose column that SAP had affinity for a synthetic

'pyruvate acetal of galactose (36).
contaminant of agarose.

This sugar is a natural trace

It was shown that pyruvate acetal of galactose

,competitively inhibited the binding of SAP to Sepharose.

Therefore,

SAP may interact with certain sugar-bearing molecules in a lectin-like

manner.

II. The Clq sUbcomponent of the first component of complement.
A.

The biochemical characteristics of Clq.

Clq is one of the three subcomponent molecules comprising the

first component of complement which are held tegether in the presence
of calcium (37).

Clq is one of the most cationic proteins in human

serum with gamma electrophoretic mobility_

The concentration of Clq in

serum has been estimated to be 70-180 ug/ml (38).
of Clq has been estimated as 410,000 (39).
approximately 8.3% (40).

A, B, and C (41).

The molecular weight

The carbohydrate content is

C1q is composed of six each of three chains

Each of these chains is approximately 200 amino

acids with molecular weights of 27,000-34,800 (41).
a disulfide linked dimer with a B chain (42).

Each A chain forms

The C chains form

disulfide linked dimers with each other (42).
The amino acid content of Clq subcomponent is very unusual for a
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serum protein.

It contains a high level of hydroxylysine and

hydroxyproline (43).

Furthermore, Clq contains a higher than normal

level of glycine (42).

This unusual amino acid and carbohydrate

composition suggested that Clq was collagen-like.
Collagen is composed of polypeptide chains containing the triplet
Gly-X-Y where the X residue is often proline and the Y residue is often
hydroxyproline or hydroxylysine (43).

In the Clq molecule, each chain

forms a minor helix and triplets of these polypeptide chains (A, B, C)
together form a major helix.

Six of these major helices associate with

each other comprising the collagen-like fibril (44,45).

By electron microscopic studies, Clq exhibits avery unusual
structure.

Six collagen-like strands are joined at one end to form a

stem whereas at the other end the strands deviate forming a structure
resembling an umbrella (46).

Each collagen-like strand of the umbrella

terminates in a non-collagen-like globular portion (46).

At the

point where the collagen-like fibrils diverge, the bend in the stem is
somewhat flexible and acts as a hinge facilitating the enzymatic Clr
and CIs SUbcomponents in their reactive functions (47).
Interestingly, Clq has the ability to bind three bivalent calcium
atoms per molecule (48).
calcium-binding.

No function has been attributed to this

12
B.

Binding characteristics and the biological function of C1q.

1.

The interaction of Clq with Clr and else

The majority of Clq in circulation is found in association with

the other sUbcomponents of CI.

Two molecules of Clr and two of CIs are

associated with one molecule of Clq in the presence of calcium forming

the 'reactive Cl molecule (48).

The calcium requirement has been shown

to be necessary for the dimerization of CIs and not for the interaction

of Clr with Cls (48).

Both Clr and CIs possess proteolytic

activity and are virtually indistinguishable

(49,50).

by amino acid sequence

When activated, both enzymes are serine proteases (51).

The

mechanism of activation of Clr is still unknown, but activated Clr
results in proteolytic cleavage and activation of Cls (52).

The

mechanism for the Clr mediated activation of CIs has been explained by
the structural conformation of the Cl molecule.

By electron micrograph

the Clr2C1s2 tetramer was shown to be made up of dimers of Clr with
molecules of Cls at either end forming an

"s" shaped linear chain (51).

Dimers of Clr do not require calcium (53), but the presence of calcium
allows the dimerization of the two terminally located Cls molecules

forming a circular chain.

This circle-shaped tetramer has been shown

to form in a manner which incorporates the umbrella-like portion of Clq

(54). When incorporated into the Clq molecule, Clr2C1s2 is maintained
in a conformation which prevents activation.

It has been suggested
""

that when the angle of bend of the six strands of Clq is altered, for
example, by interaction with immune complexes, the two Clr molecules
become associated in a manner which allows auto-activation and
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subsequent cleavage of the two CIs molecules.

In this capacity, Clq

bas been characterized as an allosteric effector for the activation of

2.

The interaction of Clq with Cl inhibitor.

Cl inhibitor is an inhibitor of many serine proteases including
Clr, CIs (56,57), plasmin (57), kallikrein (57,58,59), activated plasma

thromboplastin antecedent (Xla) (60), and Hagemon Factor (XIIa) (60).

In the case of CIr and CIs, one of these molecules forms a very stable
complex with one molecule of Cl inhibitor (56,61).
required for this reaction (62).

Calcium is not

Cl inhibitor preferentially inhibits

activated CIs when in the pres·ence of noncomplexed activated Clr (63).

Inhibition by Cl inhibitor is greatly enhanced by heparin (28,62,64,

65).
Recently, a role for CI inhibitor in control of activation of Cl
has been postulated (66).

The mechanism of control of CI activation by

CI inhibitor was desc.ribed in the above investigation to be a result of

the proximity of Cl inhibitor to Cl.

The activation of Cl by specific

activators such as immune complexes could not be inhibited by Cl
inhibitor in the fluid phase, however, in the case of non-immune
activators, inhibition was more efficient.

3.

The interaction of Clq with immunoglobulin.

Each of the six globular heads of Clq has the ability to bind one
immunoglobulin molecule (67).

Activation of Cl requires binding of Cl

by more than one immunoglobulin, i.e. aggregated by antigen, heat, or
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other means.

However, it has been demonstrated that Cl exhibits weak

binding to monomeric immunoglobulin

(68).

The Fe regions of polymeric

IgM, IgG3' IgGl, and IgG2 all show the ability to activate Cl with
decreasing reactivity in the order listed
IgE all fail to bind Cl

4.

(69).

IgG4, 19A, IgD,

and

(39,69,70,71,72,73).

The interaction of Clq with basement membrane.

Several basement membrane constituents have been demonstrated to
interact with Clq.

The interaction of Clq with fibronectin has been

well characterized.

Fibronectin is a high molecular weight glyco-

protein found in plasma and in basement membrane associated with

collagen (74).

Fibronectin is the only connective tissue associated

protein besides SAP which is also a normal plasma constituent

(75).

The interaction of fibronectin with Clq has been shown to occur with a
higher level of binding to the collagen-like stem region than to the
globular

heads~

although significant binding to the globular heads was

also demonstrated

Laminin~

(76).

another basement membrane component, has also been

demonstrated to bind Clq

(77).

Laminin is a large glycoprotein which

is found in basement membrane in association with type IV collagen

(78).

Thus, it appears there may be a family of proteins which bind

Clq and alter its ability to interact with other reactive proteins.

5.

The interaction of Cl with bacteria and microorganisms.

Cl has been shown to be activated by several bacterial species

including Klebsiella, Salmonella, E. Coli

(79-83)~ streptococcus

(84),
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and Staphylococcus (76).

In

addition~

Cl has been shown to be

activated by mycoplasma (85)~ retroviruses (86-90), and parasites such
as Schistosoma (91)~ and Trypanosoma (92).

6.

The interaction of Cl with other activators.

Several proteins have been shown to activate Cl besides
immunoglobulin.

C-reactive protein, a homologue of SAP, has been shown

to activate Cl (93,94), as has myelin basic protein (95,96).

Certain

carbohydrates (97,98)~ polyanions such as heparin (99,100,101),
~

polynucleotides (102)~ and lipids (98,103) have been shown to activate
C1.

The large repertoire of molecules with which Cl interacts is

indicative that there exists a family of reactive SUbstances which
facilitate immunoregulation and immune clearance through nonspecific
mechanisms.

7.

The C1q receptor.

Many cell types exhibit the ability to bind free Clq.

These

include lymphocytes (104,105,106), B lymphocytes (107)~ monocytes

(107), null cells (107), polymorphonuclear leukocytes (107), platelets
(108,109), and endothelial cells (110).

The binding of Clq to these

cell surfaces was shown to be specific, reversible, saturable, and of
moderately high affinity indicating that it is receptor mediated

(104,107).
receptor

The collagenous portion of Clq was shown to bind the

(lo4~107).

Because native C1 was unable to bind the receptor,

it was suggested that the binding site on Clq for the receptor was
masked when complexed with Clr2C1s2.

Thus~

binding of free Clq to such

16
receptor-bearing cells facilitates the interaction of Clq with its
reactive ligands on the surface of immunoreactive cells.

It seems

likely that Clq is of great importance in regulation of the immune
response at an early stage of activation.

17
REFERENCES
1.

Glenner, G.G., W. Terry, M. Harada, C. Isersky, and D. Page.
"Amyloid fibril protein: proof of homology with immunoglobulin
light chains by sequence analyses."

2.

Science 172; 1150-1151, 1971.

Cathcart, E.J., F.R. Cromerford, and A.S. Cohen. "Immunologic

studies on a protein extracted from human secondary amyloid. 1t

N.

Eng. J. Med. 273; 143-146, 1965.

3.

Husby, G., P.J. Ranlov, K. Sletten, and G. Marhang. "The amyloid in
Familial Amyloid Cardiomyopathy of Danish origin is related to
pre-albumin."

4.

Clin. Exp. Immunol. 60; 207-216, 1985.

Gejyo, F., T. Yamada, S. Qdani, Y. Nakagawa, M. Arakawa, T.
Kunitomo, H. Kataoka, M. Suzuki, Y. Hirasawa, T. Shirahama, A.S.
Cohen, and K.M. Schmid.

"A new form of amyloid protein associated

with chronic hemodialysis was identified as;12-microglobulin.n
Biochem. Biophys. Res. Comm. 129; 701-706, 1985.

5.

Pepys, M.B., M.L. Baltz, F.C. deBeer, R.F. Dyck, S. Holford, S.M.
Breathnach, M.M. Black, C.P. Tribe, D.J. Evans, and A. Feinstein.
"Biology of serum amyloid P component."

Ann. N. Y. Acad. Sci. 389;

286-298, 1982.

6.

Schneider, H.M., and M. Laos. " Amyloid P-component - a special
type of collagen?"

7.

Virchows Arch. Cell Pathol. 29; 225-228,1978.

Dyck, R.F., C.M. Lockwood, M. Kershaw, N. McHugh, V.C. Duance,
M.L. Baltz, and M.B. Pepys. "Amyloid P component is a constituent

18
normal human glomerular basement membrane."

J. Exp. Med. 152;

1162-1174, 1980.

8.

Breathnach,

S.M.~

J.M. Melrose, B. Bhogal, F.e. deBeer, R.F.

Dyck,G. Tennent, M.M. Black, and M.B. Pepys. "Amyloid P component
is located on elastic fibre microfibrils in normal human tissue."
Nature 293; 652-654, 1981.

9.

Binette,

P.~

M. Binette, and E. Calkins. "The isolation and

identification of the p-component of normal plasma proteins."
Biochem. J. 143; 253-254, 1974.

10.

Osmand~

A.P., B. Friedenson, H.

Gewurz~

R.H. Painter, E.

Hoffman, and A. Shelton. "The characterization of C-reactive
protein and the complement sUbcomponent C1t as homologous proteins
displaying cyclic pentameric symmetry (pentraxins)."

Proc. Natl.

Acad. Sci. USA 74; 739-743,1977.
11.

Pinteric, L. and R.H. Painter. ttElectron microscopy of serum

amyloid protein in the presence of calcium: alternative forms of
assembly of pentagonal molecules in two-dimensional lattices."
Can. J. Biochem. 57; 727-736, 1979.
12.

Abernathy, T.J. and B.S. Avery.

"The occurrence during acute

infections of a protein not normally present in blood.

I.

Distribution of the reactive protein in patients' sera and the
effect of calcium on the flocculation with the C-polysaccharide
of pneumococcus."

J. Exp. Med. 73: 173, 1941.

19
13.

Pepys, M.B., M.L. Baltz, R.F. Dyck, F.e. deBeer, D.J. Evans,

A.. Feinstein, C.P. Milstein, E.A. Munn, N. Richardson, J.F •
Davies, K. Gomer, A.S. Cohen, M. Skinner, and G.G.B. Klaus.
"studies of serum amyloid p-component (SAP) in man and animals. tt
In: Amyloid and Amyloidosis, Proceedings of the Third
International Symposium on Amyloidosis, edited by G.G. Glenner, P.
Pinho e Costa, and A. Falcao de Freitas.

Amsterdam: Excerpta

Medica, 1980, p. 373.

14. Anderson, J.K. and J.E. Mole. "Large scale isolation and partial
primary structure of human plasma amyloid P-component."

Ann.

N.Y. Acad. Sci. 389; 216-233, 1982.

15.

Mantzouranis, E.C., S.B. Dowton, A.S. Whitehead, M.D. Edge, G.A.P.
Bruns, and H.R. Colton. "Human serum amyloid P component: cDNA
isolation, complete sequence of pre-serum amyloid P component, and
localization of the gene to chromosome 1.11

J. Biol Chern. 260;

7752-7756, 1985.

16.

Thompson, A.R. and D.L. Enfield. "Human plasma P component:
Isolation and c.harac.terization."

17

Assimeh, S.N. and R.H. Painter.

Biochem. 17; 4304-4311, 1978.
liThe identification of a

previously unrecognized sUbcomponent of the first component of
complement."
18.

J. Immunol.

115; 482-487, 1975.

Levo, Y., B. Frangione, and E.D. Franklin. "Amino acid sequence
similarities between amyloid P component, Clt, and CRP." Nature

268; 56-57, 1977.

20
19.

Painter, R.H. "Evidence that Clt (Amyloid P-component) is nota
subcomponent of the first component of complement (Cl)."

J.

Immunol. 119; 2203-2205, 1977.

20.

Cooper, N.R. and R.S. Ziccardi.

"Amyloid P component (C1t) and

complement: Lack of physical or functional relationship." Mol.
Immunol. 16; 821-827,1979.

21.

Hutchcraft, C.L., H. Gewurz, B. Hansen, F.R. Dyck, and M.B. Pepys.
"Agglutination of complement-coated erythrocytes by serum amyloid
P-component."

22.

Hutchcraft,

J. Immunol. 126; 1217-1219, 1980.

e.L.,

B. Hansen, V.O. Harling, and H. Gewurz. "Binding

reactivities of serum amyloid P-component."

Ann. N.Y. Acad. Sci.

389; 449-450, 1982.
23.

deBeer, F.e., M.L. Baltz, S. Holford, A. Feinstein, and M.B.
Pepys. "Fibronectin and C4-binding protein are selctively bound by
aggregated amyloid P component." J. Exp. Med. 154; 1134-1149,

1981.
24.

Wright, S.D., L.S. Craigmyle, and

S.C. Silverstein. "Fibronectin

and serum amyloid P component stimulate C3b- and
phagocytosis in cultred human monocytes."

C3bi-mediated

J. Exp. Med. 158;

1338-1343, 1983.

25.

Boxer, G.J., N.U. Bang, J.W. Ferroni, and M.D. Benson. "Plasma
amyloid P-component inhibits heparin activity." Blood

50(Suppl.);260,1977.

21

26.

Pepys, M.B., G.J. Becker, R.F. Dyck, A. McGraw"
Merton, and D.P. Thomas.

"Studies of human serum amyloid

P-component (SAP) in relation to coagulation."

27.

P. Hilgard, R.E.

Clin. Chim. Acta

Ku, C.S.L., and B.A. Fiedel. "Modulation of fibrin clot formation
by human serum amyloid P component (SAP) and heparin."

J. Exp.

Med. 158; 767-780, 1983.
28.

Caughman, G.B., R.J. Boackle, and J. Vesely. "A postulated

mechanism for heparin's potentiation of C1 inhibitor function."

19; 287-295, 1982.

Mol Immunol.

29.

Boackle, R.J., G.B. Caughman, J. Vesely, G. Medgyesi, and H. H.Fudenberg.

"Potentiation of Factor H by heparin: A rate-limiting

mechanism for inhibition of the alternative complement pathway."
Mol. Immunol. 20; 1157-1164, 1983.
30.

Waugh, D.F., and M.A. Fitzgerald. "Quantitative aspects of

antithrombin and heparin in plasma."

Amer. J. Physiol. 184;

627-638, 1956.
31.

Fiedel, B.A., R.M. Simpson, and H. Gewurz. "Ac.tivation of
platelets by modified C-reactive protein."

Immunol. 45; 439-447,

1982.
32.

Fiedel, B.A., C.S.L. Ku, J .M. Izzi, and H. Gewurz. "Selective
inhibition of platelet activation by the amyloid P-component of
serum."

J. Immunol. 131; 1416-1419, 1983.

22

33.

Leva, Y. and

s.

Wollner. "Effects of serum amyloid P component on

human lymphocytes. 1t

Int. Arch. Allergy apple Immun. 77;

322-325~

1985.

34.

Uhlenbruck, G., D. Karduck, H. Haupt, and H.G. Schwick.
proteins with lectin properties?"

z.

Immun.-Forsch. 155;

262-266, 1979.

35.

Li,

J.J.~

M.E.A. Pereira, R.A. DeLellis, and K.P.W.J. McAdam.

"Human amyloid P component: A circulating lectin that modulates
immunological responses."

36.

Scand. J. Immunol. 19; 227-236, 1984.

Hind, C.R.K., P.M. Collins, D. Reno, R.B. Cook, D. Caspi, M.L. _
Baltz, and M.B. Pepys. "Binding specificity of serum amyloid P
component for the pyruvate acetal of galactose."

J. Exp. Med.

159; 1058-1069, 1984.

37.

Lepow, I. G.B. Naff, E.W. Todd, J. Peosky, and C.F. Hinz.
"Chromatographic resolution of the first component of human
complement into three activities." J. Exp. Med. 11; 983-1008,

1963.
38.

Ziccardi, R.J., and N.H. Cooper. "The subunit composition and
sedimentation properties of human C1. ft

J. Immunol. 118;

2047-2052, 1977.
39.

Calcott, M.A., and H.J. Muller-Eberhard. " Clq protein of human
complement."

Biochem. 11; 3443-3450, 1972.

23
40.

Porter, R.R., and K.B.M. Reid. " Activation of the complement
system by antibody-antigen complexes: the classical pathway."
Adv. Protein Chem.

41.

1;1-71, 1979.

Reid, K.B.M., D.M. Lowe, and R.R. Porter. "Isolation and
complement, from human and rabbit sera."

Biochem. J.

130;

749-763, 1972.
42.

Reid, K.B.M. and R.R. Porter. "Subunit composition and structure
of subcomponent C1q of the first component of human complement."
Biochem. J. 155; 19-23, 1976.

43.

Reid, K.B.M. "Amino acid sequence of the N-terminal forty-two
amino acid residues of the C chain of subcomponent C1q of the
first component of human complement."

Biochem J. 161; 247-251,

1977.
44.

Reid, K.B.M. and R.R. Porter.

"The structure and mechanism of

activation of the first component of complement."

Contemp. Top.

Mol. Immunol. 4, 1-22, 1975.
45.

Muller-Eberhard, H.J. "Chemistry and reaction mechanisms of
complement."

46.

Adv. Immunol. 8; 1-80, 1968.

Porter, R.R. and K.B.M. Reid.

"The biochemistry of complement."

Nature 275; 699-704, 1978.
47.

Schumaker, V.N., P.H.

~oon,

G.W. Seegan, and C.A. Smith.

"Semi-flexible joint in the Clq subunit of the first component of

24
human complement."

48.

J. Mol. Biol. 148; 191-197, 1981.

Villiers, C.L., G.J. Arlaud, R.H. Painter, and M.G. Colomb.
"Calcium binding properties of the CI sUbcomponents C1q, C1r, and
CIs."

49.

FEBS Lett. 117; 289-294, 1980.

Sim, R.B. and R.R. Porter. "Isolation and comparison of the
proenzyme and activated forms of the human serum complement
sUbcomponents C1r and CIs." Biochem. Soc. Trans. 4; 127-129,
1976.

50.

Cooper, N.R. and R.J. Ziccardi. " The nature and reactions of
complement enzymes. In: Proteolysis and Physiological Regulation,
Vol. 11, edited by Ribbons, D.W. and K. Brew. New York: Academic
Press, 1976, p. 167-187.

51.

Arlaud, G.J. and J. Gagnon. "Complete amino acid sequence of the
catalytic chain of human complement subcomponent C1r."
Biochemistry 22, 1758-1764, 1983.

52.

Tschopp, J., T. Schulthess, J. Engel, and J.C.

Eaton.

"Antigen-independent activation of the first component of
complement C1 by chemically cross-linked rabbit IgG-oligomers."
Febs Lett. 112; 152-154, 1980.
53.

Valet, G. and N.R. Cooper.

"Isolation and characterization of the

proenzyme form of the C1r subunit of the first complement
component."

J. Immunol. 112, 339-345 and 1667-1673, 1974.

25

54.

Poon, P.H., V.N. Schumaker, M.L. Phillips, and C.J. strang.
"Conformation and restricted segmental flexibility of CI, the
first component of human complement." J. Mol Biol.

168; 563,

1983.

55.

Lin, T.Y. and D.S. Fletcher. "Activation of a complex of Clr and
CIs subcomponents of human complement CI by the third subcomponent
Clq."

56.

J. Biol Chem.

Ziccardi, R.J. and N.R. Cooper.
cleavage."

57.

255; 7756-7762, 1980.
"Activation of Clr by proteolytic

J. Immunol. 116; 504-509, 1976.

Ratnoff, O.D., J. Pensky, D. Ogston, and G.B. Naff. "The
inhibition of plasmin, plasma kallikrein, plasma permeability
factor, and the Clr subcomponent of the fist component of
complement by serum Cl esterase inhibitor."

J. Exp. Med. 129;

315-331, 1969.
58.

Landerman, N.S., M.E. Webster, E.L. Becker, and H.E. Ratcliffe. "
Hereditary angioneurotic edema. II. Deficiency of inhibitor for
serum globulin permeability factor and/or plasma kallikrein."

J.

Allergy 33; 330-341, 1962.

59.

Gigli, I., J.W. Mason, R.W. Colman, K.F. Austen.
plasma kallikrein with the Cl inhibitor."

"Interaction of

J. Immunol. 104;

574-581, 1970.
60.

Forbes, C.D., J. Pensky, and O.D. Ratnoff. "Inhibition of
activated Hagemon factor and activated plasma thromboplastin

26
antecedent by purified C1 inactivator."

J. Lab. Clin. Med. 76;

809-815, 1970.

61.

Harpel,P.C. and N.H. Cooper.

"Studies on human plasma C1

inactivator-enzyme interactions. I. Mechanisms of interaction with
C1s, plasmin, and trypsin."
62.

J. Clin. Invest. 55; 593-604, 1975.

Sim, R.B., G.J. Arlaud, and M.G. Colomb. "Kinetics of reaction of
human Cl-inhibitor with the human complement system proteases Clr
and C1s." Biochim. Biophys. Acta 612; 433-439, 1980.

63.

Heboul, A. G.J. Arlaud, R.B. 8im, and M.G. Colomb. "A simplified
procedure for the purification of Cl-inactivator from human
plasma.

Interaction with the complement components Clr and CIS."

FEBS Lett. 79; 45-50, 1977.

64.

Rent, H., R. MYrrman, B.A. Fiedel, and H. Gewurz. "Potentiation of
Cl-esterase inhibitor activity by heparin."

Clin. Exp. Immunol.

232; 264-271, 1976.
65.

Nagaki, K. and S. Inai. "Inactivation of the first component of
human complement (C1INA).

Enhancement of C1INA activity against

Cls by acidic mucopolysaccharides."

Int. Arch. Allergy Appl.

Immunol. 50; 172-180, 1976.

66.

Ziccardi, R.J. "A new role for C1-inhibitor in homeostasis:
Control of activation of the first complement component." J.
Immunol. 128; 2505-2508, 1982.

27

67.

Knobel, H.R., C. Heusser, M.L. Rodrick, and H. Isliker. "Enzymatic
digestion of the first componen"t of human complement (C1q)."
J. Immunol. 112; 2094-2101, 1974.

68.

Ziccardi, R.J. "Demonstration of the interaction of native C1 with
monomeric immunoglobulins and C1 inhibitor."

J. Immunol. 134;

2559-2563, 1985.

69.

Schumaker, V.N., M.A. Calcott, H.L. Spiegelberg, and H.J.
Muller-Eberhard.

"Ultracentrifuge studies of the binding of IgG

of different subclasses to the C1q subunit of the first component
of complement."
70.

Biochemistry 15; 5175-5181, 1976.

Muller-Eberhard, H.J. "Complement." Annu. Rev. Biochem. 44,
697-724, 1975.

71.

Augener, W., H.M. Grey, N.R. Cooper, and H.J. Muller-Eberhard.
"The reaction of monomeric and aggregated immunoglobulins with
Cl. n Immunochemistry 8; 1011-1020, 1971.

72.

Ishizaka, T., K. Ishizaka, T. Borsos, and H. Rapp. "C1 fixation by
human isoagglutinins: fixation of Cl by gamma-G and gamma-M but
not by gamma-A antibody."

73.

J. Immunol. 97; 716-726, 1966.

Isenman, D.E., K.J. Dorrington, and R.H. Painter. "The structure
and function of immunoglobulin domain. II. The importance of
interchain disulfide bonds and the possible role of molecular
flexibility in the interaction between immunoglobulin G and
complement." J. Immunol. 114; 1726-1729, 1975.

28
14.

Hedman, K. A. Valerie, and J. Wartionaara. "External fibronectin
of cultured human fibroblasts is predominantly a matrix protein."
J. Cell BioI. 76; 748-760, 1918.

75.

Kuusela, P., E. Ruoslahti, E. EngvaIl, and A. Valerie.
"Immunological interspecies cross-reactions of fibroblast surface
antigen."

76.

Immunochem. 13; 639-642, 1976.

Sorvillo, J., I. Gigli, and E. Pearlstein. "Fibronectin binding to
complement subcomponent C1q."

77.

Biochem. J. 226; 207-215, 1985.

Bohnsack, J.F., A.J. Tenner, G.W. Laurie, H.K. Kleinman, G.R.
Martin, and E.J. Brown. "The C1q subunit of the first component-of
complement binds to laminin: A mechanism for the deposition and
retention of immune complexes in basement membrane."

Proc. Natl.

Acad. Sci. 82; 3824-3828, 1985.
, 78.

Hynes, R. and K. Yamada. "Fibronectins: Multifunctional modular
glycoproteins."

79.

J. Cell BioI. 95; 369-377, 1982.

Loos,M. "Antibody-independent activation of CI, the first
component of complement."

Ann. Immunol. (Inst. Pasteur) 133C;

165-180, 1982.
80.

Loos, M., B. Welleck, R. Thiesen, and W. Opferkuch.
"Antibody-independent interaction of the first component of
complement with gram-negative bacteria."
1978.

Infect. Immun. 22; 5-9,

29
81.

Clas, F. and M. Loos. "Antibody-independent binding of the first
component of complement (C1) and its subcomponent C1q to the Sand

R forms of Salmonella minnesota."

Infect. Immun. 41; 1138-1140,

1981.

82.

Betz, S.J. and H. Isliker. "Antibody-dependent interactions
between Escherichia coli J5 and human complement components."

J.

Immunol. 127; 1748-1754, 1981.

83.

Tenner, A.J., R.J. Ziccardi, and N.R. Cooper. "Antibodyindependent Cl activation by E. coli."

J. Immunol. 133; 886-891,

1984.
84.

Levy, N.J. and D.L. Kasper.

"Antibody-independent and -dependent

opsonization of Group B streptococcus requires the first component
of complement Cl. n

85.

Infect. Immun. 49; 19-24, 1985.

Bredt, W., B. Wellek, H. Brunner, and M. Loos. "Interactions
between mycoplasma pneumoniae and the first components of
complement."

86.

Infect. Immun. 15; 7-12, 1977.

Cooper, N.R., F.e. Jensen, R.M. Welsh, and M.B.A Oldstone. ttLysis
of RNA tumor viruses by human serum: direct antibody-independent

triggering of the classical complement pathway."

J. Exp. Med.

144; 970-984, 1976.
87.

Welsh, R.M., N.R. Cooper, F.e. Jensen, and M.B.A Oldstone.
serum lyses RNA tumour ,viruses. If

Nature 257; 612-614, 1975.

"Human

30

88.

Welsh, R.M., F.C. Jensen, N.R. Cooper, and M.B.A. Oldstone.
"Inactivation of lysis of oncornaviruses by human serum."
Virology 74, 432-440, 1976.

89.

Sherwin, S.A., R.E. Benveniste, and G.J. Todaro.

"Complement-

mediated lysis of type-C virus: effect of primate and human sera
on various retroviruses." Int. J. Cancer 21; 6-11, 1978.

90.

Gallagher, R.E., A.W. Schrecker, C.A. Walter, and R.C. Gallo.
"Oncornavirus lytic activity in the serum of gibbon apes. U

J.

Natl. Cancer lnst. 60; 677-682, 1978.

91.

Santoro, F., M. Ouaissi, J. Pestel, and A. Capron. "Interaction.between Schistosoma mansoni and the complement system: binding of
Clq to schistosomula."

92.

J. Immunol. 129; 2886-2891, 1980.

Musoke, A.J. and A.F. Barbet. "Activation of complement by
variant-specific surface antigen of trypanosoma brucei."

Nature

270; 438-440, 1977.
93.

Claus, D.R., J. Siegel, K. Petras, A.P. Osmand, and H. Gewurz.
"Interaction of C-reactive protein with the first component of
human complement."

94.

J. Immunol. 119; 187-192, 1977.

Kaplan, M.R. and J.E. Volanakis. "Interaction of C-reactive
protein complexes with the complement system. I. Consumption of
human complement associated with the reaction of C-reaction
protein with pneumococcal C-polysaccharide and with the choline
phosphatides, lecithin and sphingomyelin."

J. Immunol. 112;

31
2135-2147~

95.

Cyong,

1974.

J.c.,

S.S. Witkin, B. Rieger, E. Barbarese, R.A. Good, N.K.

Good, N.K. Day. "Antibody-independent complement activation by
myelin via the classical complement pathway."

J. Exp. Med. 155;

587-598, 1982.
96.

Vanguri, P., C.L. Koski, B. Silverman, and M.L. Shin. "Complement
activation by isolated myelin: activation of the classical pathway
in the absence of myelin-specific antibodies."

Proc. Natl.Acad.

Sci. USA 79; 3290-3294, 1982.

97.

Schultz, D.R. and P.I. Arnold.
complement:
hydrates. tt

98.

"The first component of human

on the mechanism of activation by some carboJ. Immunol. 126; 1994-1998, 1981.

Loos, M., D. Bitter-Sverman, and M.P. Dierich. "Interaction of the
first (C1), the second (C2), and the fourth (C4) component of
complement with different preparations of bacterial lipopolysaccharides and with lipid A."

J. Immunol. 112; 935-940,

1974.
99.

Raepple, E., H.V. Hill, and M. Laos. "Mode of interaction of
different polyanions with the first (Cl, C1), the second (C2), and
the fourth (C4) component of complement. I. Effect on fluid phase

C1 and on C1 bound to EA or to EAC4."

Immunochemistry 13;

251-155, 1976.
100. Rent,

R.~

N. Ertel, R. Einstein, and H. Gewurz.

"Complement

activation by interaction of polyanions and polycations. I.

32
Heparin-protamine induced consumption of complement."

J. Immunol.

114; 120-124, 1975.
101. Fiedel, B.A., R. Rent, R.

~horman,

and H. Gewurz. "Complement

activation by interaction of polyanions and polycations."
Immunology 30; 161-169, 1976.
102. Peltier, A.P., L. Cyna, and A. Dryll. "In vitro study of a
reaction between the complement system and cellular DNA."
Immunology 35; 779-784, 1978.
103. Cooper, N.R. and D.C. Morrison. "Binding and activation of the
first component of complement by the lipid A region of
lipopolysaccharides."

J. Immunol. 120; 1862-2868, 1978.

104. Tenner, A.J. and N.R. Cooper. "Analysis of receptor-mediated C1q
binding to peripheral blood mononuclear cells."

J. Immunol. 125;

1658-1664, 1980.
105. Sobel, A.T. and V.A. Bokisch. "Receptor for Clq on peripheral
human lymphocytes and human lymphoblastoid cells."

Fed. Proc. 34;

965, 1975.
106. Gabay, Y. H. Perlman, and A.J. Sobel. "A rosette assay for the
determination of C1q receptor-bearing cells."

Eur. J. Immunol. 9;

797-801, 1979.

107. Tenner, A.J. and N.H. Cooper. "Identification of types of cells in
human perpheral blood that bind C1q."

J. Immunol. 126; 1174-1179,

33
1981.
108. Wantier, J.L., H. Souchon, K.B.M. Hied, A.P. Peltier, and J.P.
Caen. "Studies on the mode of reaction of the first component of
complement with platelets: interaction between collagen-like
portion of Clq and platelets."

Immunochemistry 14; 763-766, 1977.

109. Suba, E.A. and G. Csako. "Clq (C1) receptor on human platelets:
inhibition of collagen-induced platelet aggregation by C1q (C1)
molecules."

J. Immunol. 117; 304-308, 1976.

110. Shadworth, M.F., P.H. Cunningham, and P.S. Andrews. "The demonstration of complement C1q and Fc-IgG receptors on the surface of
human endothelial cells."

Fed. Proc. 38; 1075, 1979.

CHAPTER 2

ROLE OF HUMAN SERUM AMYLOID P COMPONENT IN IMMUNE CLEARANCE
THROUGH INTERACTIONS WITH Clq AND

Fab~
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INTRODUCTION
Serum amyloid P component (SAP) is a 9.5 S

~l-glycoprotein

(1)

found in plasma, amyloid deposits, and covalently linked to elastic
fiber microfibrils in the connective tissue of glomerular basement
membrane, skin, blood vessels, lung and gut (2,3).

This 250,000 dalton

glycoprotein is made up of ten identical 23,500 dalton subunits
non-covalently linked to form two face-to-face pentagonal structures

(4).

The similarity in structure between SAP, C-reactive protein (CRP) ,

and hamster female protein (HFP) has led to the classification of these
pentameric proteins as pentraxins (4,5).
not an acute phase reactant (6).

In humans, SAP, unlike CRP, is

SAP has been found in all vertebrate

species studied, and SAP has never been found to be deficient in any
individual (7).

Because of the evolutionary conservation of the

biochemical properties of SAP, the role of SAP is assumed to be of
importance.

While no biological function for SAP has thus far been

reported, SAP has been speculated to interact with or be involved with
fibronectin, c4 binding protein (8), platelet activation (9),
inflammation (10), complement (11,12), and coagulation (13).

The

specific role that SAP plays in the above systems is not understood.
SAP was, at one time, named CIt, a presumed fourth subcomponent of
the C1 molecule (14).

These authors found that SAP was co-purified with

Cl when serum was passed through a Sepharose-IgG column.

Later, it was
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discovered that SAP had a calcium-dependent affinity for Sepharose
(15), and Cooper and Ziccardi (16) showed by a series of comparisons
that SAP neither functionally nor physically interacted with the C1
molecule.

In the latter work, the inability of SAP to interact with C1

was examined by sucrose density gradient ultracentrifugation, CH50
assay, and Cl hemolytic assay.

It is noteworthy

that the latter two

experiments were performed in the presence of gelatin.

The reported

variable effects of SAP on complement hemolytic activity (16) suggested
to

us that gelatin might be interfering with the SAP-C1 interaction

(i.e. when C1 is in the fluid-phase as opposed to the EA-bound phase).
Cooper and Ziccardi (16) also reported that SAP did not associate with
C1 in sucrose density gradient ultracentrifugation, however, the calcium
concentration (O.15 mM) in the gradient was 1/10 physiological level
which may have adversely affected the ability of SAP to interact with
C1.

Furthermore, the relative effect of sucrose on SAP binding was not

compared with other density gradient media.
In a similar study (14), when serum was examined for the
association of SAP with C1 by ultracentrifugation, it was found that in
a Ficoll gradient, SAP appeared to be associated with C1, whereas use of
a sucrose gradient gave variable results.

Furthermore, in the above

study, the association of SAP with C1 was demonstrated in a gradient
containing 1 mM calcium, whereas in the presence of EDTA no association
of SAP with C1 could be demonstrated.
It was shown earlier by Cooper and Ziccardi (16) that SAP might
have

a calcium-dependent affinity for IgG.

It seemed possible,

therefore, that SAP could affect the interaction of aggregated IgG with
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complement.

Results presented here are consistent with the postulation

that SAP interacts with both C1q and with the Fab region of aggregated
IgG.

MATERIALS AND METHODS
Isolation of human SAP:
Serum amyloid P component was prepared as previously described by
Anderson and Mole (17).

Basically, air-contaminated plasma was obtained

from the American Red Cross and delipidated by centrifugation for three
hours at 2000 g.

This clarified plasma was precipitated by addition of

15 gIl barium chloride, and the precipitate was washed and resolubilized
in 0.15M sodium citrate, pH 1.6.

The resulting solution was

precipitated with ammonium sulfate, and the fraction precipitating
between 30% and 60% was collected and resolubilized in O.OlM phosphate
buffer, pH 7.2, dialyzed against the same buffer, and chromatographed on
a 2x15 cm DE-52 ion exchange column.

A 500 ml gradient from O.OM - O.7M

NaCl in phosphate buffer was applied, and the fraction containing SAP
eluted at approximately a.2M NaCl.
using rocket

~unoelectrophoresis

SAP was quantitatively detected
or by measuring the absorbence using

the extinction coefficient E1% = 18.2 at 280 nm (18). Goat antiserum to
1cm
P component (SAP) was obtained from Atlantic Antibodies, Scarborough,
MA.

SAP was further purified using affinity chromatography on Sepharose

4B in a.1M TRIS, 0.15M NaCl, 5mM CaCl2.

SAP was subsequently eluted by

application of O.lM TRIS, 0.15M NaCl (without CaCl2).

The eluted

protein was concentrated with polyethylene glycol and dialyzed against
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O.005M Na-5,5' diethyl barbituate, 0.15M NaCl, pH 7.4 (VBS).

The

veronal buffered saline did not contain gelatin.
The SAP preparation was examined for purity using PAGE in a

9~

gel,

and only one high molecular weight band was detected at approximately
200,000 daltons when 10-50 ug purified SAP was applied to the gel in
the absence of SDS.

When this SAP preparation was examined in

the presence of SDS, only one low molecular weight band appeared at
23,000

daltons.

Only one band was apparent in PAGE.

There was only

one precipitin arc in the SAP preparation when crossed IEP was
performed against antiserum to whole human serum.
Isolation of human Clq:

C1q was isolated as described by Yonemasu and Stroud (19) and
dialyzed against VBS.

Isolated C1q was quantitated using the extinction

coefficient E1% = 6.82 at 280 nm (20). In a 5%-30% gradient SDS-PAGE,
lcm
. . there was one band in the Clq preparation at 410,000 daltons when 10-25
ug purified Clq was applied to the gel.
Iodination of SAP and Clq:
Clq and SAP were radiolabelled with 1 2 5INa utilizing 30 ul
chloramine T (1 mg/ml) at a concentration of 1 mCi/34 ug Clq or 1mCi/40
ug SAP in 250 ul VBS.

The reaction was stopped by addition of 30 ul

Na-metabisulfite (2 mg/ml).

Radiolabelled Clq and SAP were separated

from free 1 251 by gel filtration on a G-50 column.
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Immunoglobulin and immunoglobulin fragments:
IgG,

FC~,

and

Fab~(Chrompure

proteins) were obtained from Jackson

Immunoresearch Labs Inc., Avondale, PA.
by heating at 63°C for 30 min.

Aggregation of IgG was achieved

All preparations were diluted to defined

concentrations in VBS.
C3 conversion in crossed immunoelectrophoresis (IEP):
Activation of serum complement C3 was determined by measuring the
proportion of cleaved C3 using crossed IEP against antiserum to C3
(21).

Antiserum to C3 was obtained from Atlantic Antibodies,

Scarboruogh, MA.

Serum at a final concentration of 1:3 was incubated-

for 60 min at 37°C in VBS with a final concentration of 1.5mM CaC12' ImM
MgS04 in the presence or absence of activators before electrophoresis
was performed.
Affinity chromatography of 1 2 5I-C1q to SAP on Sepharose 4B:
A 3 ml column of Sepharose 4B was prepared by incubating the beads
overnight at 4°c in the presence of 2% BSA in VBS.
equilibrated in VBS containing 5mM CaC12.

This column was

Each sample applied to the

column contained 8 ul 125I-Clq (34 ug/ml), and 10 ul of either VBS, SAP
(155 ug/ml in VBS) , or 5% BSA with a final concentration of 5 mM CaC12.
All samples were incubated for 10 min. at 37°C and diluted to 250 ul in
VBS containing 5 mM CaC12 before application to the column.

Fractions

were collected in 1 ml volumes with a flow rate of 6 ml/hour.
in presence of BSA was used to represent maximum 125I-Clq.
binding was calculated as follows:

1 2 5I-Clq

Percent
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Sum of fraction cpm in presence of SAP
Sum of fraction cpm in presence of BSA

1 -

X 100

Pepsin digestion of Clq molecule:
Digestion of Clq with pepsin (Sigma) followed the procedure described by
Reid (22).

Briefly, pepsin was incubated with Clq at a 1:30 ratio for

20 hours at 37°C.

The collagen-like fragments of the Clq molecule were

separated from the remaining proteins by gel filtration on a 1x30 em
G-200 column.

Fractions containing the collagen-like portion were

lyophilized and reconstituted in VBS.
SAP crossed IEP:
Interaction of SAP with various proteins (e.g. Clq) was determined
by crossed IEP against 0.67% goat antiserum to SAP.

In these stUdies

SAP was incubated with the test sUbstance for 10 min. at 37°C in VBS
which contained 1.5 mM calcium (VBS++) before crossed IEP.

Note that

the concentration of Ca++ is at near phyiological level and is ten times
higher than the level used in standard complement buffers.
Microtitre solid phase binding assay:
Polystyrene microwells (Removastrips, Dynatec Lab., Alexandria,
Va.) were utilized to examine the binding of 1 2 5I-SAP to various test
proteins by a method previously described (23).

Briefly, 300 ul of the

test protein at various concentrations in VBS was incubated in the
microwells for 60 min. at room temperature.

After washing once with

VBS, the microwells were blocked with 300 ul 1% BSA in VBS for 30 min.
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at room temperature.

Wells were washed once with VBS, and 300 ul

125I-SAP at 17-33 ng/ml in VBS++ was allowed to incubate in the wells
overnight at 4°c.

Control wells without test protein consisted of VBS

buffer only (maximum) and 1% BSA only (background).

These control wells

were used to calculate maximum and minimum binding of 125I-SAP.

Percent

binding was calculated as follows:
(cpm in test well) - (cpm in BSA well)
(cpm in buffer well) - (cpm in BSA well)

X 100

RESULTS
Interaction with Clq:
When SAP was first incubated with various concentrations of Cl
(Cordis) for 10 min at 37°C in VBS++, there was a loss of detectable
SAP, as determined by subsequent crossed IEP against antiserum to SAP.
In order to d,etermine whether SAP interacted with the Clq SUbcomponent
of Cl several approaches were used.
Various concentrations of Clq in VBS++ were incubated with a
constant amount of SAP for 10 min. at 37°C and mixtures were examined
for SAP migration utilizing crossed IEP.

A loss of precipitable SAP

observed when using a ratio of 67 ug Clq: 40 ug SAP (Fig. 1).
2.5 mM

A 1.0 to

concentration of Ca++ was required for the above interaction.

Addition of 0.04 M EDTA completely blocked the interaction.
A second method for studying the interaction of SAP with C1q
utilized the affinity of SAP for agarose (15).

In these studies, the

role of SAP in mediating the binding of radiolabelled 125I-Clq was
measured.

was

12 5I-Clq (15.1 ug/ml) was first incubated with SAP (86.1
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ug/ml) in VBS++ for 10 1 at 37°C, then the mixtures were applied to a 3
ml Sepharose 4B column in VBS containing 5 mM Ca++.
was retained (Fig. 2).

70% of the 1 2 5I-Clq

When CaCl2 was subsequently removed from the

column by washing with VBS minus calcium, 71% of the bound 1 2 5I-Clq was
recovered (Table 1).
VBS++.

1 2 5I-Clq alone was applied to Sepharose 4B in

In these controls less than

1%

of 125I-Clq was retained.

Interaction of SAP with the collagen-like regions of Clq:
Because of the similarities between the stem region of Clq and
collagen, the interaction of SAP with collagen was examined.
studies a microtitre solid-phase binding assay was used.

For these

1 2 5I-SAP was

shown to interact with both type I collagen (Collagen Corp., Calif.) and
type IV collagen (kindly donated by Dr. Gary Grotendorst, Department of
Rheumatology/Immunology, MUSC) in a dose dependent manner (Fig. 3).

The

degree of binding of SAP with type IV collagen was 2.7 times higher than
with type I collagen.

Both interactions were optimized by using a

concentration of 30-40 ug/ml collagen with 17-33 ng 1 2 5I-SAP.
Furthermore, 125I-SAP interacted with gelatin at levels similar to its
interaction with type IV collagen (data not shown).
In order to directly determine whether SAP might interact with the
collagen-like stem of Clq, Clq was digested with pepsin, and the stem
was isolated from the protease and remainder peptides.

125I-SAP bound

to the Clq stem region as determined by the solid phase microtitre assay

(Fig. 4).
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Interaction of SAP with IgG and

Fab~:

SAP (40 ug/ml) was incubated with purified IgG (50-100 ug/ml) for
10 min at 37°C.

By crossed IEP against antiserum to SAP, it appeared

that SAP interacted with IgG when calcium (1.5 mM) was present.

In

other words, the SAP immune precipitates observed in the second
direction of crossed IEP diminished in the presence of IgG and this
effect was Ca++ dependent.
In addition, a microtitre solid-phase binding assay was utilized in
order to further investigate the interaction of SAP with IgG.

The

binding of 1 25I-SAP to ~obilized IgG occurred in a dose dependent
manner.

The most efficient binding of 1 25I-SAP occurred when the

microwells were coated with 20 ug/ml IgG followed by 125I-SAP at a
concentration of 33 ng/ml (Fig. 5).
with

The interaction of immobilized IgG

125I-SAP was shown to occur in the presence of calcium.

In the

absence of calcium, no binding' of l25I-SAP to IgG was observed.
When the pepsin fragments of IgG were examined by the same type of
solid-phase binding assay it was found that 125I-SAP interacted with the
Fab~-

portion in a dose dependent manner (Fig. 6).

of SAP to the

Fc~

However, no binding

portion was detected (Fig. 7).

In order to examine the effect of SAP on the interaction of Clq
with immunoglobulin and vice versa, 125I-SAP was first complexed to Clq
and then tested for binding to immobilized IgG or to its
fragments.

Fab~'

and

FC~

A mixture with a final concentration of 44 ng/ml Clq to

33 ng/ml 125I-SAP in VBS++

was incubated 10 min. at 37°C.

This
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mixture was allowed to incubate in the microwells which had previously
been coated with either IgG (33 ng/ml), Fab,... (66 ng/ml), or Fcc( (66
ng/ml) and washed.

It was found that when 125I-SAP was first complexed

with Clq the binding of 125I-SAP-Clq complexes to IgG or Fab~ was 24% as
compared to free 125I-SAP (not pre-mixed with Clq) (Table 2).

Further-

more, when 125I-SAP was first complexed with Clq there was no increase
in binding to 125I-SAP to Fc~/as compared to free 125I-SAP.
In a similar set of experiments, 125I-SAP was first complexed with
either IgG or

Fab~and

then tested for binding to immobilized Clq.

A

mixture with a· final concentration of 33 ng/ml IgG to 33 ng/ml
125I-SAP in'VBS++ was incubated 10 min. at 37°C.

This mixture was

allowed to incubate in the microwells which had previously been coated
with Clq (133 ng/ml).

In this experiment, when 1 2 5I-SAP was first

complexed with IgG, 73.7% of the 1 2 5I-SAP bound to immobilized Clq as
compared to free 125I-SAP (without IgG).

Complexes of Fab~ (66 ng/ml)

and 1 2 5I-SAP (33 ng/ml) showed 38.1% 1 2 5I-SAP bound to immobilized Clq
as compared to free 125I-SAP.
Activation of the complement pathway by SAP:
An individual has been previously characterized with a reduced
level of Cl inhibitor (24).

When SAP was incubated for 1 hr at 37°C

with this sera, SAP activated complement as determined by C3 conversion.
Approximately 50% less C3 conversion was observed when SAP was incubated
with normal sera.

The C3 conversion caused by isolated SAP (0.12 mg/ml)

in the Cl inhibitor deficient serum was comparable to the C3 conversion
caused'by 0.5 mg/ml heat-aggregated IgG in the same serum (Fig. 8).

As
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expected, when exogenous Cl inhibitor was added before the incubation of
SAP with Cl inhibitor deficient serum, the activation of complement by
SAP was restricted (Fig. 9).

These results support the concept that

the activation of the complement pathway by the isolated SAP might be
through the interaction of SAP with the Cl molecule.
DISCUSSION
There has been some controversy about the association of SAP with
Cl.

Originally, SAP was reported to be a sUbcomponent of Cl (14), but

later, it was reported that SAP and Cl had no functional or physical
interaction (16).

In this study, the ability of SAP to interact with Cl

was re-examined.
The binding of Clq-SAP mixtures were studied using affinity
chromatography.

In this system, the ability of SAP to bind agarose

(Sepharose 4B) in the presence of calcium was utilized.

When 1 2 5I-Clq

was first pre-incubated with SAP, 70% or greater of the 125I-Clq was
retained by the Sepharose.

Furthermore, when the calcium was cleared

from the column, 71% of the bound 1 2 5I-Clq was recovered.

In control

studies it was shown that 125I-Clq (without SAP, but with BSA) was not
significantly retained by Sepharose 4B.

These experiments indicated

that SAP was probably interacting with Clq and mediating the Clq binding
to the agarose.

In order to further sUbstantiate the interaction of SAP with Clq,
SAP crossed IEP was performed.
concen~rations

In these experiments, various

of Clq or intact Cl were pre-incubated with a constant
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amount of SAP prior to electrophoresis.

It was observed that there was

a loss of precipitable SAP as compared to controls without Cl or Clq.
Furthermore, the greatest loss of detectable SAP occurred with
approximately equimolar ratios of SAP to Clq and in the presence of
calcium.
SAP crossed IEP on agarose has properties which can be used to
detect binding of SAP to Clq.

For example, SAP interacts with agarose

but only in the presence of calcium.

In addition, Clq has a gamma

mobility, and this limits the ability of SAP when complexed with Clq to
migrate in a crossed IEP system at pH 8.6-8.8.

Indeed, complexes of SAP

with Clq did not migrate into the antiserum-containing agarose.

Thus-,

the lack of precipitate formation in the second direction of SAP crossed
IEP was used as an indirect measure of binding of SAP to Clq.
The Clq molecule is composed of a collagen-like stem, six strands
of which form an umbrella-like structure and terminate in proteinacious
globular heads (25).

The globular heads of Clq have an affinity for the

Fc portion of the immunoglobulin molecule (26).

To examine the

interaction of SAP with the collagen-like stem of Clq, the ability of
SAP to interact with the pepsin digest of Clq was investigated.

In a

microtitre solid phase binding assay, it was observed that binding of
1 25I-SAP to the immobilized Clq stem fragments occurred in a dose
dependent manner in the presence of calcium.

Therefore, SAP probably

interacts with the stem of Clq, unlike IgG which interacts with the
globular heads.
In further examining whether SAP might interact with the collagen-
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like stem, the ability of SAP to interact with collagen types I and IV
was comparatively investigated.

Using a microtitre solid-phase binding

assay, it was shown that 125I-SAP interacted with collagen types I and
IV in a calcium dependent manner.

The interaction of SAP with type IV

collagen was 2.7 times higher than with type I collagen.

Furthermore,

in the same type of assays, 125I-SAP interacted with gelatin at levels
similar to its interaction with type IV collagen.
Collagen type IV is located in epithelial and endothelial basement
membranes (27).

Neither fibers nor fibrils are detectable, rather

microfibrils appear to be randomly distributed forming a felt-like
matrix (28,29).

It has been reported that SAP (amyloid P component)

binds covalently to elastic fiber microfibrils in basement membranes and
that SAP is released by collagenase (2,3).

Based on the finding that

SAP shows a calcium dependent binding to type IV collagen, it is likely
that SAP is located on collagen microfibrils in basement membranes.
Tissue injury resulting from physical trauma or from infection by
microorganisms initiates a series of events involving complement which
increase vascular permeability.

One of the tissue SUbstances to which

serous fluids are exposed during this process is SAP (amyloid P
component) which is immobilized on basement membranes.

At a site of

trauma, the interaction of tissue-bound SAP with serum Clq may allow SAP
to interact with the complement pathway.
It is possible that SAP, either in circulation or in tissue, binds
to SUbstances on the surfaces of microorganisms (e.g. zymosan, 30), and
when aggregated may facilitate complement activation via the classical
pathway.
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The interaction of SAP with gelatin suggested that gelatin would
interfere with experimental testing of the interaction of SAP with other
proteins in assays which contain gelatin.

Gelatin is often a component

of buffers used in complement hemolytic assays.

Since we determined

that gelatin binds SAP, it is possible that gelatin may influence the
interaction of SAP with complement.
In a separate set of experiments, the ability of SAP to interact
with IgG,

Fab~,

and

Fc~,

phase binding assay.

was studied utilizing the microtitre solid-

These experiments established that SAP interacted

with Fabyand did not interact with

F~.

The interaction of SAP with

IgG has been suggested previously (16), however, studies on the
interaction of SAP with IgG fragments have not been reported.
In primary amyloidosis, the amyloid fibrils are composed of
chains.

A-

In these, and other types of amyloid deposits, the SAP molecule

is found bound to the fibrillar portion of the deposits in a calcium
dependent manner (31).
affinity for

Fab~

We determined that SAP has a calcium dependent

using our solid-phase binding assay.

Therefore it is

conceivable that SAP interacts with the light chain of the

Fab~region.

Such a function may be related to the deposition of SAP and of

~-

chains

as observed in amyloid deposits.
A series of microtitre solid-phase binding assays were performed to
study the ability of SAP, IgG, and Clq to interact concomitantly.

In

these studies, 125I-SAP, with or without pre-incubation with IgG or IgG
fragments was examined for binding to immobilized Clq.

After

pre-incubation of 125I-SAP with IgG, the binding of 125I-SAP to
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immobilized Clq was 26% lower than free 125I-SAP (without IgG).
However~ when 125I-SAP was pre-incubated with Fab~, the binding of

125I-SAP to immobilized Clq was 62% lower than free 1 2 5I-SAP (without
Fab~).

This indicated that

SAP for Clq.

Fab~

probably blocked the binding site on

Furthermore, the fact that there was a greater loss of

125I-SAP binding to Clq when 1 2 5I-SAP was pre-incubated with Fab7 than
with intact IgG can be explained by the lack of the Fe region which is
known to bind to Clq.
In other studies, 1 2 5I-SAP, with or without pre-incubation with
Clq, was examined for binding to immobilized IgG or Fab~.

When 1 2 5I-SAP

was first pre-incubated with Clq, the binding of 125I-SAP to both IgG .
and Fab~ was 76% lower than free 1 2 5I-SAP (without Clq).

The presence

or absence of Fc region did not make a significant difference in the
percent inhibition.

If SAP binds to the Clq stem region proximate to

the globular heads, then SAP may restrict the Clq globular heads from
properly interacting with

FC~.

Such an effect would neutralize the

Clq-Fc interaction.
Since SAP was found to interact with Clq, it was of interest to
determine the ability of SAP to influence the activation of complement.
When SAP was incubated with serum containing decreased levels of Cl
inhibitor, C3 conversion occurred.

It was demonstrated that the

activation of complement by SAP in Cl inhibitor deficient serum was
restricted by addition of exogenous Cl-inhibitor giving further evidence
that isolated SAP may interact with the classical complement pathway.
In summary, we suggest that SAP interacts with Clq in a calcium-
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dependent manner.

Because SAP also interacts with collagen types I and

IV, we speculate that the interaction of SAP with Clq is through the
collagen-like region.

This postulation was supported by the binding of

SAP to the residual fragments after pepsin digestion of the Clq
molecule.

We have also demonstrated that SAP interacts with

Fab~.

The

ability of SAP to activate the complement pathway in Cl inhibitor
deficient serum is restricted in the presence of sufficient levels of
exogenous Cl inhibitor.

In areas where Cl inhibitor is depleted, i.e.

by binding to activated Hageman Factor, kallikrein, or plasmin (32,33)
SAP mediated effects on Cl activation may be enhanced.
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Table 1. Retention of 125I-Clq

SAP on Sepharose 4B

1 25I-Clq ELUTED

125I-Clq NOT RETAINED

SAMPLE APPLIED

CPM
125I_C1q + BSA

by

219873.0

-+

Percent

CPM

Percent

96.4

8110

3.6

168.2

-+ 1068.8

\

125I-Clq

+

SAP

69204.0
:. 1177.6

31.5 a

107382.3

-+

71.3 b

1144.1

a)

For calculations, 1 25I-Clq + BSA vas used to represent maximum 1 25I-Clq
unbound fractions.

b)

For this calulation, 125Clq + SAP retained (difference betveen 125I-Clq in
presence of BSA and SAP) was used to represent maximum in bo~nd fraction.

in
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Table 2. INTERACTION OF 125I-SAP WITH Clq AND IgG CONCOMITANTLY

Well-coat

Sample a

Percent Binding b

IgG

l25I-SAP + VBS

100

(10 mg!ml)

l25I-SAP + Clq

24

Fab-.r

125I-SAP + VBS

100

(20 mg/mJ..)

125I-SAP + Clq

24

"125I-SAP + VBS

100

Clq

1 25I-SAP + IgG

74

(40 mg/ml)

125I-SAP + Faby-

38

a)

For these experiments, 10 ul of 125I-SAP (10ug/ml) and 10 ~l of the test
sUbstaoce (as described) vere added to the pre-coated microtitre vells
containing 280 ul VBS, 1.5 mM calcium, and incubated overnight at 4°C.

b)

For calculations, 125I-SAP + VBS alone vas used to represent maximum
binding.
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Fig. 1

SAP crossed immunoelectrophoresis demonstrating diminishing
SAP precipitates in the presence of increasing concentrations
of Clq. 1) SAP + VBS; 2) SAP + C1q (67 ug/ml); 3) SAP + C1q
(34.6 ug/ml); 4) SAP + C1q (17.3 ug/ml); 5) SAP + Clq (8.7
ug/ml). A constant amount of purified SAP (40 ug/ml) was
incubated with decreasing concentrations of purified C1q in
VBS++ for 10 min. at 37°C prior to electrophoresis. Agarose
in the second direction contained antiserum to SAP. Anode is
to the right in the first direction.
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Fig. 2

Sepharose 4B affinity chromatography profiles of 1 2 5I-C1Q with
or without SAP. 125I-C1Q was incubated with VBS (. -), 5% BSA
(_ .), or SAP (. .) for 10 min. at 370C in VBS, 5 mM calcium.
Each sample was passed through a Sepharose 4B column and the
unbound fractions collected. Bound fractions were collected by
removing calcium. Each fraction represents 1 ml.

M

•

120

I

•
•
•

0

,-

><
~
D-

O

K

100
80

•
•
•
•
•
•
•
•

UNBOUND

I

J\

1

3

B

au H0

60

...
C-

40

T-

OI

to

20

,..

C\I

0

5

7

9

11

13

15

17

19

21

fraction
0'\
~

Fig. 2

62

Fig. 3. Dose-response curves of binding of 125I-SAP in VBS++ to
immoblized collagen, types I and IV. Wells in a polystyrene
microtitre solid-phase binding assay were pre-coated with
various dilutions of collagen, type I (
) or type IV
( •••• ). After blocking with 1% BSA, a constant amount of
125I-SAP(5-10 ng/ml) in VBS++ was allowed to incubate in the
wells overnight at 4°c. The contents of the wells were
aspirated, washed, and counted.
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Fig. 4. Dose-response curves of binding of 1 2 5I-SAP to immobilized ..
Clq stem region. Wells in a polystyrene microtitre solidphase binding assay were pre-coated with various dilutions of
Clq stem region. After blocking with 1% BSA, a constant
amount of 1 2 5I-SAP(5-10 ug/ml) in VBS++ was allowed to
incubate in the wells overnight at 4°c. The contents of the
wells were aspirated, washed, and counted.
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Fig. 5. Dose-response curves of binding of 125I-SAP to immobilized.·
IgG. Wells in a microtitre sOlid-phase binding assay were
pre-coated with various dilutions of IgG. After blocking
with 1% BSA, a constant amount of 125I-SAP (5-10 ug/ml) in
VBS++ was allowed to incubate in the wells overnight at 4° C•
The contents of the wells were aspirated, washed, and
counted.
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Fig. 6. Dose-response1curves of binding of 1 25I-SAP in VBS++ to
immobilized Fab~. Wells in a polystyrene microtitre solidphase binding assay were pre-coated with various dilutions of
Fab. After blocking with 1% BSA, a constant amount of
1 2 5I-SAP (5-10' ug/ml) in VBS++ was allowed to incubate in the
wells overnight at 4°c. The contents of the wells were
aspirated, washed, and counted.
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Fig. 7. Dose-response curves of binding of 1 2 5I-SAP in VBS++ to
immobilized Fc 7 • Wells in a polystyrene microtitre solidphase binding assay were pre-coated with various dilutions of
Fe. After blo~ing with 1% BSA, a constant amount of
1 2 5I-SAP (5-10~ ug/ml) in VBS++ was allowed to incubate in the
wells overnight at 4°c. The contents of the wells were
aspirated, washed, and counted.
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Fig. 8

Complement activation as measured by C3 conversion in normal
human sera ( 111111 ) and se~ from an individual with decreased
levels of Cl inhibitor ( Q58 ). Percent conversion was
calculated as that fraction of total C3 which was converted.
Converted C3 was estimated as the area of the converted
precipitate, and total C3 was estimated as the sum of the
areas of the precipitates representing native and converted
C3. Ey student's t-test, the C3 conversion in normal sera
was significantly less than in serum with decreased levels of
Cl inhibitor when complement activation was caused by
heat-aggregted IgG (t 5 = 3.46; p~O.Ol) and by SAP (t 5 = 6.56;
p~O.OOl).
There was no significant difference in spontaneous
C3 conversion between normal sera and serum with decreased
levels of Cl inhibitor.
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Fig. 9 • C3 conversion immunoelectrophoresis of serum from an
individual with decreased levels of Cl inhibitor. 1) serum +
VBS; 2) serum + heat-aggregated IgG (0.5 mg/ml); 3) serum +
exogenous C1 inhibitor (37.5 mg/ml); 4) serum + SAP (0.12
mg/ml); 5) serum + exogenous Cl inhibitor (37.5 mg/ml) + SAP
(0.12 mg/ml). Final serum concentration was 1:3. Incubation
of serum with activators and/or inhibitors for 6~ min. at
370C was carried out in the presence of 1.5mM Ca + and 1mM
Mg++. Agarose in the second direction contained antiserum to
C3. Anode is to the right in the first direction.
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Serum amyloid P component (SAP) is a high molecular weight plasma
glycoprotein also found in basement membrane (1).

This glycoprotein

was first identified as a component of amyloid deposits bound to

,

amyloid fibrils (2).

Later, SAP was named CIt, a fourth subcomponent

of the first complement component (3).

Further evidence indicated that

the purported CIt was, in fact, SAP (4), and that SAP was not a
subcomponent of CI (5).
By examining the electrophoretic patterns of SAP by crossed rEP";
I observed a loss of precipitable SAP is in the presence of CI or Clq
when compared to SAP alone.

This indicated that in the presence of Cl

or Clq there was no interaction between SAP and anti-SAP in the second
direction of IEP.

The interaction of SAP with Cl and Clq was calcium

dependent, and in the presence of EDTA, the interaction was abolished.
In a second method for demonstrating the interaction of SAP with Clq, I
utilized the ability of SAP to mediate the binding of I25I-CIq to
Sepharose 4B.

When 125I-C1q was first incubated with SAP in the

presence of calcium, greater than 70% of the 1 2 5I-Clq was retained by
the column.

When the calcium was subsequently washed from the column,

71% of the bound 1 25I-Clq was recovered.

In control studies, I25I-Clq

was not retained by Sepharose 4B in the absence of SAP indicating that
I25I-Clq remained in the Sepharose column as a hitchiker on the SAP
molecule.
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The Clq molecule has a collagen-like region and six proteinacious
globular heads.

The globular heads interact with the Fc region of

immunoglobulin.

Evidence indicates that the collagen-like stem may

interact with fibronectin (6) and laminin (7), both basement membrane
constituents.

In further investigating the interaction of SAP with

Clq, I found that SAP, also a basement membrane constituent, interacted
with the collagen-like stem of Clq and with collagen, types I and IV,
in a calcium-dependent manner.

This is interesting, first of all,

because it indicates that SAP may be associated with collagen in
basement membrane.

Secondly, the affinity of the Clq stem for several

basement membrane constituents indicates there may exist a family of
molecules in damaged tissue involved in immune clearance, localization
of reactive substances, and regulation of the inflammatory response.
By using a solid phase microtitre binding assay I found that SAP
had a calcium-dependent affinity for IgG.

The interaction of SAP

itself with immunoglobulin highlights the possibility that SAP is
directly involved in regulation of the inflammatory response.

Of

considerable interest is the ability of SAP to interact with the Fab
portion of IgG in a calcium-dependent manner.

No other molecule has

been reported to interact with IgG in such a manner.
found that SAP bound Clq and IgG concomitantly.

Furthermore, I

When SAP was coupled

to the Fab of intact IgG via calcium, SAP retained the ability to bind
Clq, which in turn retained its ability to bind the Fc region of IgG.
Conversely, when SAP was coupled to Clq via calcium, SAP lost the
ability to interact with either IgG or

Fab~

These facts indicate that

in damaged tissue, SAP exposed to serous fluids may bind IgG or Clq
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depending on the concentrations present.

Regulation of the functional

capacity of Clq or IgG would be modulated by SAP in such cases.

Because SAP has affinity for Clq, I investigated the ability of
SAP to activate complement.

Interestingly, SAP itself possessed the

ability to activate complement.
~

••

Activation caused by SAP in the

fluid-phase was restricted in the presence of Cl inhibitor as opposed
to activation caused by specific activators such as heat-aggregated
IgG.

This indicated SAP probably interacted with Cl and caused

activation of the classical pathway.

Therefore, in damaged tissue

sites where Cl inhibitor has been depleted, SAP may activate Cl on the
basement membrane surface providing a mechanism for localization of ._
complement activators in tissue as opposed to activation in the
fluid-phase.

SAP has been identified in amyloid deposits bound to the fibillar
component (2). The fibrillar component has been identified as being one
of several normal plasma constituents or fragments thereof including
primarily ~ -chain (8) or serum amyloid A component (2).

Serum amyloid

A component is an acute phase reactant which has no known function.
The deposition of

A chains,

A-chain fragments, and serum amyloid A

component in amyloidosis probably occur as a result of defective
clearance mechanisms.

The identification of SAP on such fibrillar

deposits indicates SAP may be involved in the process of immune
clearance.

In summary, the ability of SAP to interact with Cl and,
specifically, Clq indicates that SAP may mediate an important role in
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modulation of the complement pathway.
with

Fab~

The ability of SAP to interact

indicates SAP may mediate an important role in modulation of

immune complex formation and activity.

Furthermore, the ability of SAP

to interact with Clq and IgG concomitantly indicates SAP may mediate
aQd important role in modulation of immune clearance and inflammation.
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